Become part of the CML community
Join the Voices of Inspiration to connect with others living with Ph+ CML in chronic phase (CP) by sharing your diagnosis and treatment story.
Ready to share your experience?
Let your journey be an inspiration for others by sharing your personal Ph+ CML-CP treatment journey. You can also email us your story at [email protected] or call 1-877-879-0245.
*SCEMBLIX was studied vs GLEEVEC® (imatinib), TASIGNA® (nilotinib), Sprycel ® (dasatinib), and Bosulif ® (bosutinib). Sprycel is a registered trademark of Bristol-Myers Squibb Company. Bosulif is a registered trademark of Pfizer Inc.